AMG 794, a Claudin 6-targeted half-life extended (HLE) bispecific T cell engager (BITE®) molecule for non-small cell lung cancer and epithelial ovarian cancer.

被引：0
|
作者：
Pham, Elizabeth [1 ]
Henn, Anja [2 ]
Sable, Beate [3 ]
Wahl, Joachim [2 ]
Conner, Kip [1 ]
Matthes, Katja [2 ]
Gupta, Shivani [1 ]
Yabut, Rodolfo [1 ]
Aeffner, Famke [1 ]
Wilson, Kristin Lewis [1 ]
Anlahr, Jonas [2 ]
Dahlhoff, Christoph [2 ]
Kale, Vijay [1 ]
Friedrich, Matthias [2 ]
Raum, Tobias [2 ]
Kufer, Peter [2 ]
Coxon, Angela [3 ]
Stienen, Sabine [2 ]
Bailis, Julie M. [1 ]
机构：
[1] Amgen Inc, San Francisco, CA USA
[2] Amgen Res Munich GmbH, Munich, Germany
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5202
引用
收藏
页数：2
相关论文
共 50 条
  • [21] AMG 757, A HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNE THERAPY AGAINST DLL3 IN SCLC: PHASE 1 INTERIM RESULTS
    Borghaei, Hossein
    Boyer, Michael
    Johnson, Melissa
    Govindan, Ramaswamy
    Rodrigues, Luis Paz-Ares
    Blackhall, Fiona
    Boosman, Rene
    Champiat, Stephane
    Hummel, Horst-Dieter
    Lai, W. Victoria
    Udagawa, Hibiki
    Chiang, Anne
    Dowlati, Afshin
    Hann, Christine
    Salgia, Ravi
    Vokes, Everett
    Minocha, Mukul
    Hashemi-Sadraei, Nooshin
    Shetty, Aditya
    Smit, Marie-Anne Damiette
    Yang, Hui
    Owonikoko, Taofeek
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A219 - A220
  • [22] Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Tran, Ben
    Horvath, Lisa
    Dorff, Tanya B.
    Greil, Richard
    Machiels, Jean-Pascal H.
    Roncolato, Felicia
    Autio, Karen A.
    Rettig, Matthew
    Fizazi, Karim
    Lolkema, Martijn P.
    Fermin, Anthony C.
    Salvati, Mark
    Kouros-Mehr, Hosein
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [23] Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).
    Owonikoko, Taofeek K.
    Champiat, Stephane
    Johnson, Melissa Lynne
    Govindan, Ramaswamy
    Izumi, Hiroki
    Lai, W. Victoria Victoria
    Borghaei, Hossein
    Boyer, Michael J.
    Boosman, Rene J.
    Hummel, Horst-Dieter
    Blackhall, Fiona Helen
    Reguart, Noemi
    Dowlati, Afshin
    Zhang, Yiran
    Mukherjee, Sujoy
    Minocha, Mukul
    Zhou, Yanchen
    Shetty, Aditya
    Sadraei, Nooshin Hashemi
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)
    Paz-Ares, L.
    Owonikoko, T. K.
    Johnson, M.
    Govindan, R.
    Izumi, H.
    Lai, V.
    Borghaei, H.
    Boyer, M.
    Boosman, R. J.
    Hummel, H-D.
    Blackhall, F.
    Dowlati, A.
    Zhang, Y.
    Mukherjee, S.
    Sable, B.
    Pati, A.
    Shetty, A.
    Sadraei, N. Hashemi
    Champiat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S720 - S721
  • [25] Ectopic claudin 6 and 18.2 expression as potential treatment target in non-small cell lung cancer.
    Mattsson, Johanna S. M.
    Micke, Patrick
    Edlund, Karolina
    Lohr, Miriam
    Jirstrom, Karin
    Berglund, Anders
    Botling, Johan
    Rahnenfuehrer, Joerg
    Marincevic, Millaray
    Ponten, Fredrik
    Ekman, Simon
    Hengstler, Jan G.
    Woell, Stefan
    Sahin, Ugur
    Tuereci, Oezlem
    CLINICAL CANCER RESEARCH, 2014, 20
  • [26] PHASE 1 STUDY OF AMG 160, A HALF-LIFE EXTENDED BITE® (BISPECIFIC T-CELL ENGAGER) THERAPY TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Dorff, Tanya
    Rettig, Matthew
    Machiels, Jean-Pascal
    Lolkema, Martijn
    Autio, Karen
    Greil, Richard
    Rottey, Sylvie
    Adra, Nabil
    Salvati, Mark
    Poon, Shirley
    Tan, Daniel
    Jurida, Gabor
    Kouros-Mehr, Hosein
    Fizazi, Karim
    Tran, Ben
    Horvath, Lisa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A207 - A208
  • [27] Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
    Aggarwal, Rahul Raj
    Rottey, Sylvie
    Aparicio, Ana
    Greil, Richard
    Reimers, Melissa Andrea
    Sandhu, Shahneen Kaur
    Zhang, Yiran
    Salvati, Mark
    Sadraei, Nooshin Hashemi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [28] Single circulating tumor cell enumeration and targeted sequencing in non-small cell lung cancer.
    Barbirou, Mouadh
    Manjunath, Yariswamy
    Miller, Amanda
    Ramirez, Arturo
    Ericson, Nolan
    Staveley-O'Carroll, Kevin F. Kevin F.
    Warren, Wes
    Li, Guangfu
    Tonellato, Peter J.
    Kaifi, Jussuf T.
    CANCER RESEARCH, 2021, 81 (13)
  • [29] Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTEimmune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).
    Aggarwal, Rahul Raj
    Aparicio, Ana
    Heidenreich, Axel
    Sandhu, Shahneen Kaur
    Zhang, Yiran
    Salvati, Mark
    Shetty, Aditya
    Sadraei, Nooshin Hashemi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] NURSING EXPERIENCE MONITORING AND MANAGEMENT OF PATIENTS RECEIVING TARLATAMAB, A BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, FOR SMALL CELL LUNG CANCER (SCLC)
    Gray, Sunshine
    Pons, Alba Silverio
    Kelley, Elaine
    McDonald, Stephanie
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
12345